Sheila Jacobs

Anti-TNF-α therapy has a beneficial effect on the metabolism of proteoglycans and glycosaminoglycans tissue in women with rheumatoid arthritis.

Results suggest that C-reactive protein testing should be repeated after at least 4 weeks.

Researchers present a new approach to investigate dose prescriptions used for exercise interventions evaluated in randomized clinical trials in rheumatoid arthritis.

The extent of monosodium urate burden measured with dual-energy computed tomography can predict the risk for disease flares in patients with gout.

Study results support the recommended use of bDMARDs in combination with csDMARDs in patients with RA.

For a more precise assessment of disease activity and treatment effectiveness in individuals with JIA, inclusion of MCP joints should be considered in the scoring system.

Higher remission rates and better quality of life were achieved in patients with rheumatoid arthritis who received a treat-to-target strategy.

Risk for type 2 diabetes, ischemic heart disease, and peripheral vascular disease was elevated among patients with psoriatic arthritis compared with the general population.

Findings suggest that repeating MRI of the sacroiliac joints after 3 months or 1 year in patients with chronic back pain and suspected axial spondyloarthritis was not useful.

Researchers quantified the incidence of orthopedic procedures in patients with psoriatic arthritis.

Patients who have been chronically exposed to hydroxychloroquine/chloroquine were not at increased risk for Alzheimer disease.

The initiation of statin therapy is associated with reduced overall mortality in patients with systemic autoimmune rheumatic diseases.

Patient-reported outcomes are independent predictors of mortality in systemic lupus erythematosus.

Data show that psoriatic arthritis acts as a strong enhancer of age-related catabolic bone damage.

Vaccination rates in patients with systemic lupus erythematosus improved significantly after the implementation of a multifaceted intervention at a rheumatology practice.

The risk for primary total knee arthroplasty is elevated in young and middle-aged adults with ankylosing spondylitis.

Prolonged antimalarial therapy and persistent creatine phosphokinase elevation resulted in an increased risk for abnormal brain natriuretic peptide and cardiac troponin.

Improvements in the rate of ocular complications and visual impairment have been noted in pediatric patients with noninfectious uveitis who are treated with biologic agents.

The main risk factors leading to knee replacement surgery in patients with osteoarthritis include disease severity, symptoms, and high BMI.

Statin exposure was significantly associated with histologically confirmed idiopathic inflammatory myositis.

Overall obesity is associated with an increased risk for gout and with higher serum urate concentrations.

The safety profile of adalimumab in pediatric patients with polyarticular juvenile idiopathic arthritis, enthesitis-related arthritis, psoriasis, and Crohn disease was similar across indications.

Consistent data show that treatment with biologic therapy significantly improves work productivity and activity impairment among patients with axial spondyloarthritis.

Researchers assessed the predictive accuracy of MRI-detected erosions in patients with undifferentiated arthritis.

Researchers explored the co-occurrence of ankylosing spondylitis and diffuse idiopathic skeletal hyperostosis.

Patients with gout have an increased risk for total joint replacement, which may not be reduced by urate-lowering treatment.

The overall safety profile of ixekizumab in psoriatic arthritis remained consistent with that reported in the initial 24-week, double-blind study period.

The use of accelerometry data has led to the discovery of performance phenotypes of lumbar spinal stenosis and osteoarthritis.

Lupus nephritis in combination with impaired renal function is strongly associated with the presence of atherosclerosis in patients with systemic lupus erythematosus.

ABT-122 demonstrated acceptable tolerability and maintenance of efficacy at 36 weeks in patients with RA or PsA receiving background methotrexate.